Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.96−0.10 (-1.24%)
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Novavax total assets
Total assets on the balance sheet at the end of each period.
Novavax's total assets was $955.58M at Jun 30, 2026. For fiscal 2025 it was $1.18B, down 24.6% from the year before. Over ten years it grew 11.8% a year on average. The highest annual figure on record is $2.58B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.18B | -24.6% |
| FY2024 | Dec 31, 2024 | $1.56B | -13.2% |
| FY2023 | Dec 31, 2023 | $1.80B | -20.4% |
| FY2022 | Dec 31, 2022 | $2.26B | -12.3% |
| FY2021 | Dec 31, 2021 | $2.58B | +62.8% |
| FY2020 | Dec 31, 2020 | $1.58B | +815.0% |
| FY2019 | Dec 31, 2019 | $172.96M | -16.8% |
| FY2018 | Dec 31, 2018 | $207.98M | -31.2% |
| FY2017 | Dec 31, 2017 | $302.49M | -23.3% |
| FY2016 | Dec 31, 2016 | $394.30M | +2.1% |
| FY2015 | Dec 31, 2015 | $386.04M | +39.9% |
| FY2014 | Dec 31, 2014 | $276.00M | +17.4% |
| FY2013 | Dec 31, 2013 | $235.13M | +129.7% |
| FY2012 | Dec 31, 2012 | $102.35M | +53.7% |
| FY2011 | Dec 31, 2011 | $66.58M | -11.0% |
| FY2010 | Dec 31, 2010 | $74.84M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $955.58M | -28.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.04B | -19.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.18B | -24.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.18B | -31.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.34B | -26.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.29B | -4.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.56B | -13.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.71B | +3.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.82B | +7.9% |
| Q1 FY2024 | Mar 31, 2024 | $1.35B | -12.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.80B | -20.4% |
| Q3 FY2023 | Sep 30, 2023 | $1.66B | -26.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.69B | -35.8% |
| Q1 FY2023 | Mar 31, 2023 | $1.54B | -45.6% |
| Q4 FY2022 | Dec 31, 2022 | $2.26B | -12.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.27B | -11.6% |
| Q2 FY2022 | Jun 30, 2022 | $2.62B | -4.6% |
| Q1 FY2022 | Mar 31, 2022 | $2.83B | +8.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.58B | +62.8% |
| Q3 FY2021 | Sep 30, 2021 | $2.57B | +171.8% |
| Q2 FY2021 | Jun 30, 2021 | $2.75B | +194.9% |
| Q1 FY2021 | Mar 31, 2021 | $2.61B | +695.1% |
| Q4 FY2020 | Dec 31, 2020 | $1.58B | +815.0% |
| Q3 FY2020 | Sep 30, 2020 | $944.02M | +472.8% |
| Q2 FY2020 | Jun 30, 2020 | $932.23M | +392.2% |
| Q1 FY2020 | Mar 31, 2020 | $328.07M | +48.2% |
| Q4 FY2019 | Dec 31, 2019 | $172.96M | -16.8% |
| Q3 FY2019 | Sep 30, 2019 | $164.81M | -34.2% |
| Q2 FY2019 | Jun 30, 2019 | $189.39M | -33.7% |
| Q1 FY2019 | Mar 31, 2019 | $221.32M | -19.8% |
| Q4 FY2018 | Dec 31, 2018 | $207.98M | -31.2% |
| Q3 FY2018 | Sep 30, 2018 | $250.48M | -25.0% |
| Q2 FY2018 | Jun 30, 2018 | $285.81M | -19.7% |
| Q1 FY2018 | Mar 31, 2018 | $276.07M | -23.6% |
| Q4 FY2017 | Dec 31, 2017 | $302.49M | -23.3% |
| Q3 FY2017 | Sep 30, 2017 | $334.08M | -27.3% |
| Q2 FY2017 | Jun 30, 2017 | $355.71M | – |
| Q1 FY2017 | Mar 31, 2017 | $361.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $394.30M | – |
| Q3 FY2016 | Sep 30, 2016 | $459.63M | – |
See a number that looks wrong?